Analysts forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce sales of $7.32 million for the current quarter, Zacks reports. Three analysts have provided estimates for Pieris Pharmaceuticals’ earnings. The highest sales estimate is $9.01 million and the lowest is $5.10 million. Pieris Pharmaceuticals reported sales of $11.69 million during the same quarter last year, which would suggest a negative year over year growth rate of 37.4%. The firm is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.24 million for the current fiscal year, with estimates ranging from $20.40 million to $35.58 million. For the next fiscal year, analysts anticipate that the firm will report sales of $25.46 million, with estimates ranging from $13.33 million to $34.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.85 million. Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%.

Several research analysts have recently commented on PIRS shares. Cowen reiterated a “buy” rating on shares of Alector in a research report on Monday, May 13th. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Monday, June 17th. Zacks Investment Research downgraded Eisai from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Robert W. Baird started coverage on TJX Companies in a report on Monday, May 13th. They issued an “outperform” rating and a $63.00 price target on the stock. Finally, ValuEngine raised XOMA from a “sell” rating to a “hold” rating in a report on Friday, May 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Pieris Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $5.67.

Shares of PIRS traded up $0.35 during mid-day trading on Monday, hitting $4.75. The stock had a trading volume of 583,259 shares, compared to its average volume of 270,476. The stock has a market capitalization of $216.26 million, a P/E ratio of -9.50 and a beta of 1.25. The company’s fifty day moving average price is $4.45. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $5.85.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers grew its stake in shares of Pieris Pharmaceuticals by 51.5% during the 4th quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 22,720 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $43,000. Dimensional Fund Advisors LP acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $374,000. Two Sigma Investments LP acquired a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $159,000. Finally, Bank of America Corp DE grew its stake in shares of Pieris Pharmaceuticals by 793.1% during the 4th quarter. Bank of America Corp DE now owns 277,370 shares of the biotechnology company’s stock worth $739,000 after purchasing an additional 246,312 shares during the period. 59.70% of the stock is currently owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: What is systematic risk?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.